NXGL 8-K: Board change

Filed with the SEC on · accession 0001493152-26-053107

NXGL filed a 8-K (current report) with the SEC on Nov 18, 2026. NexGel elected Aviv Argaman as an independent director effective November 12, 2026, and appointed him to a newly formed special committee of independent directors to evaluate and negotiate a proposed merger with Fountainhead LifeSciences and its affiliates.

Summary of the filing

NexGel elected Aviv Argaman as an independent director effective November 12, 2026, and appointed him to a newly formed special committee of independent directors to evaluate and negotiate a proposed merger with Fountainhead LifeSciences and its affiliates. Argaman, through his firm Asymmetry Point, holds $2.0 million of the company's convertible notes that would convert into common stock only upon completion of the merger.

Key details

Aggregate principal amount of convertible notes purchased by Asymmetry Point in 2026 private placements$2.0M
Shares of common stock into which Asymmetry Point's notes would convert upon completion of the mergershares 364K
Conversion price per share for Asymmetry Point's notes$6
Shares of common stock for accrued interest through September 30, 2026 to be received by Asymmetry Point upon conversionshares 6K
Reduced exercise price of Asymmetry Point's existing note warrants$13
Original exercise price of existing note warrants covering 41,667 shares$16
RegistrantNexGel, Inc.
Investment firm founded and managed by director aviv argaman; holder of company convertible notesAsymmetry Point Capital LLC
Fund managed by asymmetry point capital llc; holder of company convertible notesAsymmetry Point LP
Proposed merger counterpartyFountainhead LifeSciences
Affiliate of proposed merger counterpartySequence LifeScience, Inc.
Affiliate of proposed merger counterpartyNVISION Biomedical Technologies, Inc.
Independent directorAviv Argaman
DirectorSteve Ciardiello
DirectorJerome Zeldis

✦ Ask GOAX AI about this filing — what it means for NXGL, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for NXGL?

Click here

Frequently asked questions

What did NXGL file with the SEC on Nov 18, 2026?

NXGL filed a 8-K (Board change). NexGel elected Aviv Argaman as an independent director effective November 12, 2026, and appointed him to a newly formed special committee of independent directors to evaluate and negotiate a proposed merger with Fountainhead LifeSciences and its affiliates. Argaman, through his firm Asymmetry Point, holds $2.0 million of the company's convertible notes that would convert into common stock only upon completion of the merger.

What does a board change mean for NXGL stock?

Not always. A planned retirement with a successor is usually calm; a sudden departure “effective immediately”, especially of a CFO or near results, often worries investors.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other NXGL SEC filings

Get alerts when NXGL files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days